MASSDEVICE ON CALL — Major Allergan (NYSE:AGN) shareholder Polen Capital Management isn’t getting worked up about Valeant Pharmaceuticals’ (NYSE:VRX, TSE:VRX) unsolicited $47 billion buyout offer, an executive told reporters.
Despite a cash-and-stock offer that represents a 7% premium, Allergan can do better on its own, Polen chief investment officer Dan Davidowitz told the Wall Street Journal.
Valeant announced this week that it teamed up with Pershing Square Capital Management hedge fund to offer $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan share.
"We think we could get this type of price just from another couple of years of compound earnings growth," Davidowitz told the paper. "I don’t think this is that attractive of an offer."
Allergan responded with a "poison pill" strategy, with the board of directors adopting a 1-year plan to grant 1 preferred share purchase right on each outstanding share of the company’s common stock. The strategy allows stakeholders other than the a bidder to buy additional shares at a discounted price, potentially deterring would-be bidders by increasing costs.
Mayo Clinic plans Ireland spin-out
The Mayo Clinic teamed up with ENTERPRISE Ireland to create a string of 10 spin-out firms over a period of 5 years, focusing on "market ready" medical products.
TSA-style software could help manage stroke patients
Researchers are examining airport-style pattern-recognition software to assess brain scans in better manage care for patients at risk of injury or death from intravenous thrombolysis, a key stroke treatment procedure.
"ChairBot" aims to help relieve back pain
MIT researcher Simon Hong’s electric-powered "ChairBot" could help relieve back pain by putting the user through an automated regimen of sitting and standing.